Coverage
-
March 19, 2014
A New York federal judge on Wednesday agreed to move a whistleblower suit alleging Cephalon Inc. promoted some of its drugs for off-label uses to boost sales to government-funded programs, finding that a similar suit in Pennsylvania was filed first.
2 other articles on this case.
View all »